Absci (ABSI) EBITDA Margin (2020 - 2026)
Absci (ABSI) posted EBITDA Margin of 14346.98% for Q1 2026, down 200.43% sequentially from 4775.54% in Q4 2025, and down 1199507.0% YoY from N/an in Q1 2025.
Absci (ABSI) EBITDA Margin (2020 - 2026) Analysis & Trends
Absci has reported EBITDA Margin for 7 years, with the latest figure at 14346.98% in Q1 2026.
- Quarterly EBITDA Margin fell 1199507.0% year-over-year to 14346.98% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6722.98% (down 437368.0% YoY) and the FY2025 annual result came in at 4297.04%, down 189545.0% from the prior year.
- EBITDA Margin declined to 14346.98% in Q1 2026 per ABSI's latest filing, from 4775.54% in the prior quarter.
- Over five years, EBITDA Margin peaked at 1276.74% in Q2 2023 and troughed at 14346.98% in Q1 2026.
- A 5-year average of 4938.73% and a median of 4477.29% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2026: EBITDA Margin surged 652707 bps in 2022, then plunged 1199507 bps in 2026.
- Over 5 years, EBITDA Margin stood at 6222.12% in 2022, then slipped by 18 bps to 7319.23% in 2023, then jumped by 39 bps to 4477.29% in 2024, then dropped by 7 bps to 4775.54% in 2025, then sank by 200 bps to 14346.98% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 14346.98%, 4775.54%, and 7977.25% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | -10,741.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10,741.51% |
| Mar 31, 2026 | -14,346.98% |
| Dec 31, 2025 | -4,775.54% |
| Sep 30, 2025 | -7,977.25% |
| Jun 30, 2025 | -5,293.93% |
| Mar 31, 2025 | -2,351.91% |
| Dec 31, 2024 | -4,477.29% |
| Sep 30, 2024 | -1,698.71% |
| Jun 30, 2024 | -2,104.02% |
| Mar 31, 2024 | -2,616.70% |
| Dec 31, 2023 | -7,319.23% |
| Sep 30, 2023 | -3,132.12% |
| Jun 30, 2023 | -1,276.74% |
| Mar 31, 2023 | -1,929.47% |
| Dec 31, 2022 | -6,222.12% |
| Sep 30, 2022 | -7,662.19% |
| Jun 30, 2022 | -2,882.93% |
| Mar 31, 2022 | -7,891.23% |
| Dec 31, 2021 | 1,221.78% |
| Sep 30, 2021 | -14,189.26% |